Every material Form 8-K CRESCENT BIOPHARMA, INC. has filed with the SEC since July 15, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Crescent Biopharma said in an October 15, 2026 press release that it has enrolled patients in chemotherapy combination cohorts of its ASCEND trial for CR-001, and that the FDA has cleared its CR-002 ADC for a Phase 1/2 trial. The filing gives timing for several clinical data readouts but reports no revenue, earnings, or financial results, so it is a pipeline update rather than a financial report for shareholders.
Initial CR-001 monotherapy data from ASCEND expected in the first quarter of 2027, covering more than 125 patients
Chemotherapy combination cohort data anticipated in mid-2027; Phase 3 trials of CR-001 planned to start in early 2028
CR-002 received FDA IND clearance in October 2026; APOLLO Phase 1/2 trial planned to start in the fourth quarter of 2026, with initial data in the second half of 2027
Crescent Biopharma reported a net loss of $24.8 million for the quarter ended June 30, 2026, up from $21.8 million a year earlier, with no revenue in either period. Research and development expenses rose to $19.4 million from $12.1 million, while general and administrative expenses were $8.7 million versus $8.9 million. The company said a July 2026 public offering extends its expected cash runway into the second half of 2028.
Net loss was $24.8 million, or $0.74 per basic and diluted share, for Q2 2026, compared with $21.8 million, or $4.93 per share, for Q2 2025.
R&D expenses were $19.4 million versus $12.1 million a year earlier, driven by chemistry, manufacturing and controls costs and clinical activity.
Cash and cash equivalents were $171.6 million at June 30, 2026; pro forma cash was $305.1 million after $133.5 million in net offering proceeds.
Clinical readouts for CR-001 are anticipated beginning in the first quarter of 2027.
Crescent Biopharma agreed on July 14, 2026 to sell 8,094,793 ordinary shares and pre-funded warrants for 525,897 more shares in a public offering, with gross proceeds expected to be about $125.0 million. The company says the net proceeds, together with existing cash, should fund projected operating expenses, working capital and capital expenditures into the second half of 2028, but the sale adds shares outstanding for existing holders.
Ordinary shares priced at $14.50 each; pre-funded warrants priced at $14.499 each, for 525,897 shares in total
Expected net proceeds of about $115.9 million, or about $133.5 million if the underwriters' 30-day option for 1,293,103 additional shares is exercised in full
Offering expected to close on July 16, 2026, subject to customary closing conditions
Company estimates cash will fund operations into the second half of 2028
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every CRESCENT BIOPHARMA, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →